Drugs & Therapy Perspectives, Год журнала: 2024, Номер 40(2), С. 61 - 71
Опубликована: Фев. 1, 2024
Buprenorphine extended-release (ER) injection for subcutaneous use (Brixadi®; CAM2038; hereafter referred to as buprenorphine ER) is a useful addition the treatment options opioid disorder (OUD). Brixadi® formulated using FluidCrystal® depot technology, allowing low volume prefilled syringe and steady release of over one week or month. In pivotal phase 3 trial, weekly monthly ER was non-inferior daily sublingual buprenorphine/naloxone in terms proportion opioid-negative urine samples responder rate. Based on cumulative distribution function percentage samples, superiority demonstrated with compared buprenorphine/naloxone. DEBUT patients who received reported higher more sustained satisfaction than those buprenorphine. Real-world studies have also high levels dependence. generally well tolerated, systemic safety profile similar that The most common treatment-emergent adverse events were injection-site reactions. Opioid (OUD) long-term opioids adversely affects physical mental health. Treatment OUD based psychosocial support agonists reduce illicit use, craving, HIV risk. partial agonist approved started single dose transmucosal product are already being treated drug released continuously trial OUD, not inferior response (measured by screening self-reporting use). tolerated. commonly reactions at site. Thus, OUD.
Язык: Английский